Intricon (IIN) 10-Q 2019 Q2 Quarterly report

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ____

Commission File Number: 1-5005

INTRICON CORPORATION

(Exact name of registrant as specified in its charter)

Pennsylvania	23-1069060
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)
1260 Red Fox Road
Arden Hills, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

(651) 636-9770

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $1.00 per share	IIN	Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒  Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☒
Non-accelerated filer ☐	Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The number of outstanding shares of the registrant’s common stock, $1.00 par value, on July 31, 2019 was 8,758,324.

1

INTRICON CORPORATION

I N D E X

			Page Numbers
PART I: FINANCIAL INFORMATION
	Item 1.	Financial Statements
		Consolidated Condensed Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018	3
		Consolidated Condensed Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2019 and 2018	4
		Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) for the Three and Six Months Ended June 30, 2019 and 2018	5
		Consolidated Condensed Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2019 and 2018	6
		Consolidated Condensed Statements of Equity (Unaudited) for the Six Months Ended June 30, 2019 and 2018	7
		Notes to Consolidated Condensed Financial Statements (Unaudited)	8-22
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23-33
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
	Item 4.	Controls and Procedures	34
PART II: OTHER INFORMATION
	Item 1.	Legal Proceedings	35
	Item 1A.	Risk Factors	35
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
	Item 3.	Defaults Upon Senior Securities	35
	Item 4.	Mine Safety Disclosures	35
	Item 5.	Other Information	35
	Item 6.	Exhibits	36
	Signatures		37

2

PART I: FINANCIAL INFORMATION

ITEM 1.Financial Statements

INTRICON CORPORATION

Consolidated Condensed Balance Sheets

(In Thousands, Except Per Share Amounts)

	June 30,			December 31,
	2019			2018
	(Unaudited)			(Unaudited)
Current assets:
Cash, cash equivalents and restricted cash	$	9,801		$	8,047
Short-term investments		19,688			38,093
Accounts receivable, less allowance for doubtful accounts of $308 at June 30, 2019 and $807 at December 31, 2018		9,746			11,266
Inventories		18,251			18,163
Contract assets		7,116			5,624
Other current assets		1,216			2,146
Current assets of discontinued operations		648			1,205
Total current assets		66,466			84,544
Machinery and equipment		39,155			36,725
Less:  Accumulated depreciation		26,276			25,303
Net machinery and equipment		12,879			11,422
Goodwill		9,551			10,808
Intangible assets, net		—			2,585
Operating lease right of use asset		4,396			—
Investment in partnerships		1,445			2,091
Long-term investments		15,357			—
Other assets, net		6,234			3,427
Noncurrent assets of discontinued operations		—			371
Total assets	$	116,328		$	115,248
Current liabilities:
Current financing leases	$	102		$	—
Current operating leases		1,620			—
Accounts payable		12,000			12,871
Accrued salaries, wages and commissions		3,456			4,409
Other accrued liabilities		4,260			4,031
Liabilities of discontinued operations		606			336
Total current liabilities		22,044			21,647
Noncurrent financing leases		69			—
Noncurrent operating leases		2,971			—
Other postretirement benefit obligations		355			377
Accrued pension liabilities		737			706
Other long-term liabilities		1,224			544
Total liabilities		27,400			23,274
Commitments and contingencies
Shareholders’ equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,754 and 8,664 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		8,754			8,664
Additional paid-in capital		85,729			84,999
Accumulated deficit		(4,764	)		(509	)
Accumulated other comprehensive loss		(538	)		(927	)
Total shareholders’ equity		89,181			92,227
Non-controlling interest		(253	)		(253	)
Total equity		88,928			91,974
Total liabilities and equity	$	116,328		$	115,248

(See accompanying notes to the consolidated condensed financial statements)

3

INTRICON CORPORATION

Consolidated Condensed Statements of Operations

(In Thousands, Except Per Share Amounts)

	Three Months Ended						Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2019			2018			2019			2018
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenue, net	$	29,336		$	29,448		$	58,906		$	54,026
Cost of goods sold		21,121			19,727			42,133			36,202
Gross profit		8,215			9,721			16,773			17,824
Operating expenses:
Sales and marketing		3,072			2,637			6,461			5,240
General and administrative		3,650			2,751			6,836			5,502
Research and development		1,097			1,316			2,062			2,475
Impairment loss (Note 10)		3,765			—			3,765			—
Total operating expenses		11,584			6,704			19,124			13,217
Operating income (loss)		(3,369	)		3,017			(2,351	)		4,607
Interest income (expense), net		248			(211	)		463			(405	)
Other expense, net		(272	)		(196	)		(406	)		(401	)
Income (loss) from continuing operations before income taxes and discontinued operations		(3,393	)		2,610			(2,294	)		3,801
Income tax expense		116			269			247			455
Income (loss) from continuing operations before discontinued operations		(3,509	)		2,341			(2,541	)		3,346
Loss on disposal of discontinued operations (Note 3)		(1,116	)		—			(1,116	)		—
Loss from discontinued operations, net of income taxes (Note 3)		(405	)		(333	)		(597	)		(571	)
Net income (loss)	$	(5,030	)	$	2,008		$	(4,254	)	$	2,775
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	(0.40	)	$	0.34		$	(0.29	)	$	0.48
Discontinued operations		(0.17	)		(0.05	)		(0.20	)		(0.08	)
Net income (loss) per share:	$	(0.57	)	$	0.29		$	(0.49	)	$	0.40
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	(0.40	)	$	0.29		$	(0.29	)	$	0.42
Discontinued operations		(0.17	)		(0.04	)		(0.20	)		(0.07	)
Net income (loss) per share:	$	(0.57	)	$	0.25		$	(0.49	)	$	0.35
Average shares outstanding:
Basic		8,743			6,991			8,724			6,930
Diluted		8,743			8,118			8,724			8,021

(See accompanying notes to the consolidated condensed financial statements)

4

INTRICON CORPORATION

Consolidated Condensed Statements of Comprehensive Income (Loss)

(In Thousands)

	Three Months Ended						Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2019			2018			2019			2018
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Net income (loss)	$	(5,030	)	$	2,008		$	(4,254	)	$	2,775
Realized foreign currency translation loss from discontinued operations previously unrealized, net of taxes of $0		280			—			280			—
Unrealized foreign currency translation adjustment from continuing operations, net of taxes of $0		(26	)		(257	)		(19	)		(179	)
Interest rate swap, net of taxes of $0		—			(1	)		—			3
Investment in partnerships, net of taxes of $0		—			—			118			—
Pension and postretirement obligations, net of taxes of $0		5			5			10			10
Comprehensive income (loss)	$	(4,771	)	$	1,755		$	(3,865	)	$	2,609

(See accompanying notes to the consolidated condensed financial statements)

5

INTRICON CORPORATION

Consolidated Condensed Statements of Cash Flows

(In Thousands)

	Six Months Ended
	June 30,			June 30,
	2019			2018
	(Unaudited)			(Unaudited)
Cash flows from operating activities:
Net income (loss)	$	(4,254	)	$	2,775
Loss from discontinued operations, net of tax		1,713			571
Income (loss) from continuing operations		(2,541	)		3,346
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization		1,628			1,410
Impairment loss		3,765			—
Equity in loss of partnerships		138			222
Stock-based compensation		866			667
Change in allowance for doubtful accounts		(499	)		245
Changes in operating assets and liabilities:
Accounts receivable		1,884			(1,285	)
Inventories		(262	)		(1,889	)
Contract assets		(1,492	)		(3,053	)
Other assets		798			(251	)
Accounts payable		(1,166	)		1,588
Accrued expenses		(895	)		(402	)
Other liabilities		(49	)		428
Net cash provided by operating activities of continuing operations		2,175			1,026
Net cash (used in) operating activities of discontinued operations		(96	)		(769	)
Net cash provided by operating activities		2,079			257
Cash flows from investing activities:
Purchases of machinery and equipment		(2,359	)		(1,608	)
Payments for acquisition of other assets		(667	)		—
Purchase of investment securities		(36,688	)		—
Proceeds from sale of investment securities		38,015			—
Proceeds from maturities of investment securities		1,750			—
Investment in partnerships		(247	)		(539	)
Net cash (used in) investing activities of continuing operations		(196	)		(2,147	)
Net cash (used in) investing activities of discontinued operations		(16	)		—
Net cash (used in) investing activities		(212	)		(2,147	)
Cash flows from financing activities:
Proceeds from long-term debt		—			10,833
Repayments of long-term debt		—			(9,055	)
Payment of financing leases		(54	)		—
Exercise of stock options and employee stock purchase plan shares		189			378
Withholding of common stock upon vesting of restricted stock units		(235	)		—
Net cash provided by (used in) financing activities		(100	)		2,156
Effect of exchange rate changes on cash of continuing operations		(8	)		(96	)
Effect of exchange rate changes on cash of discontinued operations		(5	)		(2	)
Effect of exchange rate changes on cash		(13	)		(98	)
Net increase in cash		1,754			168
Cash, cash equivalents and restricted cash, beginning of period		8,047			1,017
Cash, cash equivalents and restricted cash, end of period	$	9,801		$	1,185
Non-cash investing and financing:
Acquisition of machinery and equipment in accounts payable		297			1,265
Investment in partnership through liability incurred		—			187
Fitting software other asset through liabilities incurred and exchange of investment in partnership		3,012			—

(See accompanying notes to the consolidated condensed financial statements)

6

INTRICON CORPORATION

Consolidated Condensed Statements of Equity

(In Thousands)

	Shareholders’ Equity, Six Months Ended June 30, 2019 (Unaudited)
	Common Stock Number of Shares		Common Stock Amount		Additional Paid-in Capital			Retained Earnings (Accumulated Deficit)			Accumulated Other Comprehensive Loss			Non-Controlling Interest			Total Equity
Balance December 31, 2018		8,664	$	8,664	$	84,999		$	(509	)	$	(927	)	$	(253	)	$	91,974
Exercise of stock options, net		27		27		(9	)		—			—			—			18
Withholding of common stock upon vesting of restricted stock units		20		20		(255	)		—			—			—			(235	)
Shares issued under the employee stock purchase plan		3		3		67			—			—			—			70
Stock-based compensation		—		—		329			—			—			—			329
Net income		—		—		—			775			—			—			775
Comprehensive income		—		—		—			—			130			—			130
Balance March 31, 2019		8,714	$	8,714	$	85,131		$	266		$	(797	)	$	(253	)	$	93,061
Exercise of stock options, net		29		29		22			—			—			—			51
Withholding of common stock upon vesting of restricted stock units		6		6		(6	)		—			—			—			—
Shares issued under the employee stock purchase plan		2		2		48			—			—			—			50
Stock-based compensation		3		3		534			—			—			—			537
Net income (loss)		—		—		—			(5,030	)		—			—			(5,030	)
Comprehensive income		—		—		—			—			259			—			259
Balance June 30, 2019		8,754	$	8,754	$	85,729		$	(4,764	)	$	(538	)	$	(253	)	$	88,928

	Shareholders’ Equity, Six Months Ended June 30, 2018 (Unaudited)
	Common Stock Number of Shares		Common Stock Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Non-Controlling Interest			Total Equity
Balance December 31, 2017		6,900	$	6,900	$	21,581		$	(6,056	)	$	(733	)	$	(253	)	$	21,439
Exercise of stock options, net		41		41		167			—			—			—			208
Shares issued under the employee stock purchase plan		3		3		57			—			—			—			60
Stock-based compensation		—		—		333			—			—			—			333
Net income		—		—		—			757			—			—			757
Comprehensive income		—		—		—			—			86			—			86
Balance March 31, 2018		6,944	$	6,944	$	22,138		$	(5,299	)	$	(647	)	$	(253	)	$	22,883
Exercise of stock options, net		92		92		(37	)		—			—			—			55
Shares issued under the employee stock purchase plan		1		1		54			—			—			—			55
Stock-based compensation		—		—		334			—			—			—			334
Net income		—		—		—			1,992			—			—			1,992
Comprehensive income (loss)		—		—		—			—			(252	)		—			(252	)
Balance June 30, 2018		7,037	$	7,037	$	22,489		$	(3,307	)	$	(899	)	$	(253	)	$	25,067

(See accompanying notes to the consolidated financial statements)

7

INTRICON CORPORATION

Notes to Consolidated Condensed Financial Statements (Unaudited) (In Thousands, Except Per Share Data)

1. General

In the opinion of management, the accompanying consolidated condensed financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly IntriCon Corporation’s (“IntriCon” or the “Company”) consolidated financial position as of June 30, 2019 and December 31, 2018, the consolidated results of its operations for the three and six months ended June 30, 2019 and 2018 and the consolidated statement of equity and cash flows for the six months ended June 30, 2019 and 2018. Results of operations for the interim periods are not necessarily indicative of the results of operations expected for the full year or any other interim period. These consolidated condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2018 Annual Report on Form 10-K filed with the SEC.

On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its United Kingdom (UK) subsidiary within our body worn device segment. For all periods presented, the Company classified this business as discontinued operations, and accordingly, has reclassified historical financial data presented herein. See Note 3.

The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.

The Company has evaluated subsequent events occurring after the date of the consolidated financial statements for events requiring recording or disclosure in the consolidated financial statements.

2. Changes in Accounting Policies

The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In February 2016, the FASB issued ASU 2016-02 “Leases” (Topic 842). Topic 842 supersedes the lease accounting guidance previously set forth in the Accounting Standards Codification (ASC) Topic 840 “Leases,” and requires lessees to recognize a lease liability and a right-of-use asset (ROU) for all leases that extend beyond one year. The Company adopted Topic 842 with a date of initial application of January 1, 2019, which resulted in a ROU asset and lease liability of approximately $6.0M.

The Company did not apply Topic 842 retrospectively using the transition option in ASU 2018-11, “Targeted Improvements”to ASC 842, to not restate comparative periods in transition and instead to use the effective date of ASC 842, “Leases”, as the date of initial application of transition. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard which allowed us to carry forward the historical lease classification.

Changes to the Company’s accounting policies as a result of adopting Topic 842 are discussed below:

Short-term lease recognition exemption. The Company adopted the short-term lease recognition exemption as an accounting policy. Accordingly, the Company will not recognize a lease liability and ROU asset for short-term leases in transition and, post-effective date, will continue to recognize short-term leases as expense on a straight-line basis over the lease term. Renewal and purchase options for a lease will be reassessed upon the occurrence of certain discrete reassessment events: (1) the lease term is extended more than 12 months beyond the end of the previously determined lease term or (2) the lessee now concludes that the lessee’s exercise of a purchase option is reasonably certain. When a lease no longer qualifies for the short-term lease exemption, the Company will apply ASC 842 guidance on initial recognition and measurement; the commencement date of the lease for this purpose is the date of the change in circumstances.

8

Accounting for certain leases at a portfolio level. The Company accounts for leases at a portfolio level when the criteria described below are met and it reasonably expects that the application of the lease model to the portfolio will not differ materially from the application to the individual leases in that portfolio. If the applicable criteria are met, the start of the lease term is expected to be the first of the month. The criteria are:

1. Leases are similar in nature (e.g. similar underlying asset such as vehicles);

2. Leases have identical or nearly identical contract provisions, including same lessor; and

3. Leases with effective dates that fall within a narrow window of time (month or quarter) and have the same lease term

For purposes of arriving at the transition adjustment on the effective date, a total of seven vehicle leases were combined into three portfolios.

Combining lease and non-lease components into a single component. The Company elected to adopt this practical expedient for all asset classes. As a result of this election, the consideration included in the lease payments for these asset classes will be greater, resulting in a larger lease liability and ROU asset.

3. Discontinued Operations

On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its UK subsidiary within the body worn device segment. As of June 30, 2019, operations of this business have ceased, certain assets have been sold, our building lease is being transferred to a third party and the Company entered into a distribution agreement with a third party to distribute our hearing aids within the UK. The remaining assets have been written down to their net realizable value resulting in a loss on disposal of $1.0M for the three and six months ended June 30, 2019. As the disposal meets the definition of a strategic shift in accordance with ASC 205, the results of the UK operations have been classified as loss on discontinued operations, net of income taxes, in the accompanying Consolidated Condensed Statements of Operations, Comprehensive Income/Loss and Cash Flows. Current assets, noncurrent assets, and liabilities of the discontinued operations have been reclassified and reflected on the accompanying Consolidated Condensed Balance Sheets as “Current assets of discontinued operations,” “Noncurrent assets of discontinued operations,” and “Liabilities of discontinued operations”, respectively. Prior periods relating to our discontinued operations have also been reclassified to reflect consistency within our condensed consolidated financial statements.

The total assets and liabilities of the UK subsidiary at June 30, 2019 and December 31, 2018 were as follows:

	June 30,		December 31,
	2019		2018
Accounts receivable, net	$	229	$	213
Inventories		311		818
Other current assets		108		174
Current assets of discontinued operations		648		1,205
Machinery and equipment		—		436
Less:Accumulated depreciation		—		126
Net machinery and equipment		—		310
Other assets, net		—		61
Total assets	$	648	$	1,576
Accounts payable		164		320
Other accrued liabilities		442		16
Current liabilities of discontinued operations		606		336
Net assets	$	42	$	1,240

9

The loss on disposal of discontinued operations, as a result of the plan to discontinue the operations of the UK, for the three and six months ended June 30, 2019 was computed as follows:

Cash and cash equivalents	$	5
Accounts receivable, net		72
Write-down of inventory to realizable value		278
Write-down of property, plant and equipment to salvage value		298
Other assets and liabilities, net		71
Realized loss on foreign currency		280
Net assets disposed		1,004
Additional disposal costs, net		112
Loss on disposal of discontinued operations	$	1,116

The following table shows the results of the UK subsidiary’s discontinued operations:

	Three Months Ended						Six Months Ended
	June 30, 2019			June 30, 2018			June 30, 2019			June 30, 2018
Revenue, net	$	529		$	712		$	1,068		$	1,497
Cost of goods sold		321			444			667			920
Gross profit		208			268			401			577
Sales and marketing		167			244			314			481
General and administrative		446			357			684			667
Total operating expenses		613			601			998			1,148
Loss from discontinued operations, net of taxes	$	(405	)	$	(333	)	$	(597	)	$	(571	)

10

4. Segment Reporting

The Company currently operates in two reportable segments: body-worn devices and hearing health direct-to-end-consumer (DTEC). The nature of distribution and services has been deemed separately identifiable. Therefore, segment reporting has been applied. The following table summarizes certain data from continuing operations by industry segment:

At and for the Three Months Ended June 30, 2019	Body Worn Devices		Hearing Health DTEC			Total
Revenue, net	$	27,600	$	1,736		$	29,336
Impairment loss		—		(3,765	)		(3,765	)
Income (loss) from continuing operations before income taxes and discontinued operations		1,775		(5,168	)		(3,393	)
Depreciation and amortization		772		46			818
Capital expenditures		1,343		62			1,405

At and for the Six Months Ended June 30, 2019	Body Worn Devices		Hearing Health DTEC			Total
Revenue, net	$	55,540	$	3,366		$	58,906
Impairment loss		—		(3,765	)		(3,765	)
Income (loss) from continuing operations before income taxes and discontinued operations		4,356		(6,650	)		(2,294	)
Depreciation and amortization		1,498		130			1,628
Capital expenditures		2,277		82			2,359

At and for the Three Months Ended June 30, 2018	Body Worn Devices		Hearing Health DTEC			Total
Revenue, net	$	27,396	$	2,052		$	29,448
Income (loss) from continuing operations before income taxes and discontinued operations		3,108		(498	)		2,610
Depreciation and amortization		663		51			714
Capital expenditures		934		56			990

At and for the Six Months Ended June 30, 2018	Body Worn Devices		Hearing Health DTEC			Total
Revenue, net	$	50,189	$	3,837		$	54,026
Income (loss) from continuing operations before income taxes and discontinued operations		4,752		(951	)		3,801
Depreciation and amortization		1,310		100			1,410
Capital expenditures		1,542		66			1,608

11

The following table summarizes the identifiable assets (excluding goodwill) and goodwill by industry segment:

	June 30,		December 31,
For the period ended	2019		2018
Body Worn Devices:
Identifiable assets (excluding goodwill)	$	103,342	$	97,725
Goodwill		9,551		9,551
Hearing Health DTEC:
Identifiable assets (excluding goodwill)		2,787		5,139
Goodwill		—		1,257

5. Geographic Information

The geographical distribution of long-lived assets to geographical areas consisted of the following at:

	June 30,		December 31,
	2019		2018
United States	$	11,636	$	10,065
Singapore		1,148		1,240
Other		95		117
Consolidated	$	12,879	$	11,422

Long-lived assets consist of property and equipment. Excluded from long-lived assets are investments in partnerships, patents, goodwill, operating lease ROU assets and certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets.

The geographical distribution of net revenue to geographical areas for the three and six months ended June 30, 2019 and 2018 were as follows:

	Three Months Ended				Six Months Ended
Net Revenue to Geographical Areas	June 30, 2019		June 30, 2018		June 30, 2019		June 30, 2018
United States	$	24,361	$	25,255	$	48,576	$	45,714
Europe		1,568		1,172		3,232		2,665
Asia		3,219		2,699		6,728		5,167
All other countries		188		322		370		480
Consolidated	$	29,336	$	29,448	$	58,906	$	54,026

12

Geographic net revenue is allocated based on the location of the customer.

For the three and six months ended June 30, 2019, one customer accounted for 61% and 60%, respectively, of the Company’s consolidated net revenue. For the three and six months ended June 30, 2018, one customer accounted for 59% and 57%, respectively, of the Company’s consolidated net revenue.

Two customers combined accounted for 54% and 52% of the Company’s consolidated accounts receivable at June 30, 2019 and December 31, 2018, respectively.

One customer accounted for 73% and 78% of the Company’s consolidated contract assets at June 30, 2019 and December 31, 2018, respectively.

6. Investment in Partnerships

Investment in partnerships consisted of the following:

	June 30,		December 31,
	2019		2018
Investment in Signison	$	1,277	$	865
Investment in and cash advance for Soundperience		—		1,022
Other		168		204
Total	$	1,445	$	2,091

The Company has a 50% ownership interest in Signison as of June 30, 2019. Signison is accounted for in the Company’s consolidated financial statements using the equity method.

As of December 31, 2018, the Company held a 49% ownership interest in Soundperience, which was accounted for using the equity method. In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience in exchange for 1,750 Euros, our 49% ownership in Soundperience and the related license agreement. See Note 9.

7. Investment Securities

The Company currently invests in commercial paper, corporate notes and bonds with original maturities of not more than two years. The Company classifies these investments as held to maturity based on our intent and ability to hold these investments until maturity. As a result, these investments are recorded at amortized cost, which approximates fair value as of June 30, 2019. As of December 31, 2018, the Company invested in certain liquid investment securities which were classified as available for sale investments and measured at fair value based on Level 1 inputs.

13

The maturity dates of our investments as of June 30, 2019 are as follows:

	Less than one year		1-5 years		Total
Commercial Paper Original Maturities of 91 Days or More	$	6,779	$	—	$	6,779
Corporate Notes and Bonds		12,909		15,357		28,266
Total Investments	$	19,688	$	15,357	$	35,045

8. Inventories

Inventories consisted of the following at:

	Raw materials		Work-in process		Finished products and components		Total
June 30, 2019
Domestic	$	11,008	$	3,148	$	872	$	15,028
Foreign		2,648		437		138		3,223
Total	$	13,656	$	3,585	$	1,010	$	18,251
December 31, 2018
Domestic	$	10,657	$	2,484	$	1,583	$	14,724
Foreign		2,671		653		115		3,439
Total	$	13,328	$	3,137	$	1,698	$	18,163

9. Other Assets, Net

Other assets, net consisted of the following at:

	June 30,		December 31,
	2019		2018
Fitting Software	$	3,679	$	—
NXP Tech		2,063		2,259
Other		492		1,168
Total	$	6,234	$	3,427

14

In January 2019, the Company purchased the source code for self-fitting software from Soundperience for 1,750 Euros and also transferred our 49% ownership interest in Soundperience to the majority owner, positioning the Company to capitalize on the upcoming over-the-counter (OTC) hearing aid regulations. The Company has capitalized the self-fitting software within other assets, net based on the cost of the consideration transferred and will begin amortizing the asset when it is placed into service. Included in the capitalized cost of the self-fitting software is $586 of cash paid at closing as well as non-cash amounts of $869 due in future quarterly installments over the next four years, $533 due in January 2023 and $1,691 for the value of the partnership and license agreement transferred. The future payments are due in Euros and the related liabilities will be revalued based on exchange rates as of each reporting period. As of June 30, 2019, outstanding liabilities are $1,329.

10. Goodwill and Intangible Assets

During the 2019 second quarter, we continued to experience negative cash flows within our Hearing Help Express reporting unit. In addition, historical cash flows have varied from our projections. Based on these factors, management cannot put undue reliance on anticipated future cash flow generation for purposes of valuing the fair value of the reporting unit. As such, using recent historical financial information (including historical revenue, gross margins and operating expenses as level 3 inputs) as an input for undiscounted and discounted cash flows utilized in determining fair value for purposes of intangible asset and goodwill impairment testing, management determined it is more likely than not that as of June 30, 2019, the fair value of the goodwill within our Hearing Help Express reporting unit was less than its carrying amount and resulted in a non-cash impairment charge on goodwill of $1.3M and intangible assets of $2.5M.

The following summarizes the consolidated carrying amount of goodwill by period:

Carrying amount at December 31, 2018	$	10,808
Impairment of goodwill of Hearing Help Express		(1,257	)
Carrying amount at June 30, 2019	$	9,551

The following summarizes the consolidated carrying amounts of intangible assets by period:

Carrying amount at December 31, 2018	$	2,585
Amortization of intangible assets of Hearing Help Express		(77	)
Impairment of intangible assets of Hearing Help Express		(2,508	)
Carrying amount at June 30, 2019	$	—

11. Leases

The Company leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more. The Company has three leased facilities in Minnesota, two that expire in 2022 and one that expires in 2023, one leased facility in Illinois that expires in 2021 and, one leased facility in Singapore that expires in 2020, one leased facility in Indonesia that expires in 2021, and one leased facility in Germany that expires in 2022.

Certain foreign leases allow for variable lease payments that depend on an index or a market rate adjustment for the respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in profit and loss. The facility leases include options to extend for terms ranging from one to five years. Lease options that the Company is reasonably certain to execute, will be included in the determination of the ROU asset and lease liability. The Company also leases various computer equipment that include bargain purchase options at termination. These leases have been classified as finance leases.

15

As of June 30, 2019, the Company has a weighted-average lease term of 1.8 years for its finance leases, and 3.2 years for its operating leases. As of June 30, 2019, the Company has a weighted-average discount rate of 5.56% for its finance leases, and 5.49% for its operating leases. Operating cash flows from continuing operations for the six months ended June 30, 2019 from operating leases were $934. Operating cash flows from discontinued operations for the six months ended June 30, 2019 from operating leases were $84. Financing lease assets are classified as machinery and equipment within the consolidated balance sheet. During the six months ended June 30, 2019, we derecognized approximately $761 of non-cash operating lease right of use assets and liabilities from our discontinued operations and short term leases were not significant.

The following tables summarizes lease costs by type:

	Three Months Ended  June 30, 2019		Six Months Ended  June 30, 2019
Lease cost
Finance lease cost:
Amortization of right-of-use assets	$	24	$	49
Interest on lease liabilities		2		5
Operating lease cost*		457		917
Variable lease cost**		141		279
Total lease cost	$	624	$	1,250

*Operating lease cost exclude $44 and $86 related to discontinued operations of the UK for the three and six months ended June 30, 2019, respectively.

**Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our domestic and foreign building leases, excluding approximately $5 and $11 related to discontinued operations of the UK for the three and six months ended June 30, 2019, respectively.

16

Maturities of lease liabilities are as follows:

	Operating Leases			Financing Leases			Total
2019	$	928		$	57		$	985
2020		1,699			98			1,797
2021		1,361			24			1,385
2022		794			—			794
2023		222			—			222
2024 and thereafter		—			—			—
Total lease payments		5,004			179			5,183
Less: Interest		(413	)		(8	)		(421	)
Present value of lease liabilities	$	4,591		$	171		$	4,762

As previously disclosed in Note 20 of the Notes to the Consolidated Financial Statements in our 2018 Annual Report on Form 10-K, prior to the adoption of ASU 2016-02,Leases (Topic 842), the future minimum payments required under lease agreements as of December 31, 2018 were 2019 - $2,417; 2020 - $2,255; 2021 - $1,689; 2022 - $950; 2023 - $188.

12. Income Taxes

Income tax expense for the three and six months ended June 30, 2019 was $116 and $247 compared to $269 and $455 for the same period in 2018. The expense was largely due to our foreign operations. The Company has net operating loss carryforwards for U.S. federal income tax purposes. Due to the new tax legislation, there are limitations on the use of certain of the carryforwards. The Company has recorded a full valuation allowance against the deferred tax asset as of June 30, 2019.

The following was the income (loss) from continuing operations before income taxes and discontinued operations for each jurisdiction in which the Company has operations for the three and six months ended June 30, 2019 and 2018.

	Three Months Ended					Six Months Ended
	June 30, 2019			June 30, 2018		June 30, 2019			June 30, 2018
United States	$	(3,639	)	$	2,450	$	(2,755	)	$	3,300
Singapore		104			98		222			346
Indonesia		19			20		40			42
Germany		123			42		199			113
Income (loss) from continuing operations before income taxes and discontinued operations	$	(3,393	)	$	2,610	$	(2,294	)	$	3,801

The Company expects impairment losses to be an adjustment to the net loss for the three and six months ended June 30, 2019 for income tax purposes.

13. Shareholders’ Equity and Stock-based Compensation

The Company has a 2006 Equity Incentive Plan and a 2015 Equity Incentive Plan. The 2015 Equity Incentive Plan replaced the 2006 Equity Incentive Plan and new grants may not be made under the 2006 Plan.

17

Under the 2015 Equity Incentive Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”) and other equity-based awards. Under all awards, the terms are fixed on the grant date.

The Company granted 52 and 75 RSUs for the three and six months ended June 30, 2019. The weighted average closing price of the Company’s common stock on the date of grant was $23.00 and $24.09, respectively, for the RSUs granted in the three and six months ended June 30, 2019. The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units.

The Company has also granted stock options under the plans. Options granted under the plans generally vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant and have a maximum term of 10 years.

Stock award activity as of and during the six months ended June 30, 2019 was as follows:

	Outstanding Awards									Stock Option Weighted-Average		Aggregate
	Stock Options			RSUs			Total			Exercise Price (a)		Intrinsic Value
Outstanding at December 31, 2018		830			98			928		$	6.25
Forfeited, cancelled or expired		(1	)		—			(1	)		4.00
Granted		—			75			75			—
Exercised or vested		(63	)		(35	)		(98	)		4.30
Outstanding at June 30, 2019		766			138			904		$	6.41	$	16,206
Exercisable at June 30, 2019		647			—			647		$	6.28	$	11,054
Available for future grant at December 31, 2018								249
Available for future grant at June 30, 2019								179

(a) The weighted average exercise price calculation does not include outstanding RSUs

The number of shares available for future grants at June 30, 2019 does not include a total of up to 370 shares subject to options outstanding under the 2006 Equity Incentive Plan, which will become available for grant under the 2015 Equity Incentive Plan as outstanding options under the 2006 Equity Incentive Plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise of such options.

The Company recorded $537 and $866 of non-cash stock compensation expense for the three and six months ended June 30, 2019, respectively. The Company recorded $333 and $667 of non-cash stock compensation expense for the three and six months ended June 30, 2018, respectively. As of June 30, 2019, there was $2,913 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 2.15 years. The total intrinsic value of options exercised during the three and six months ended June 30, 2019 was $847 and $2,327, respectively.

18

The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through June 30, 2019, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 2 and 5 shares purchased under the plan for the three and six months ended June 30, 2019, respectively, and a total of 1 and 4 shares purchased for the three and six months ended June 30, 2018, respectively.

14. Income Per Share

The following table presents a reconciliation between basic and diluted earnings per share:

	Three Months Ended						Six Months Ended
	June 30, 2019			June 30, 2018			June 30, 2019			June 30, 2018
Numerator:
Income (loss) from continuing operations before discontinued operations	$	(3,509	)	$	2,341		$	(2,541	)	$	3,346
Loss on disposal of discontinued operations (Note 3)		(1,116	)		—			(1,116	)		—
Loss from discontinued operations, net of income taxes (Note 3)		(405	)		(333	)		(597	)		(571	)
Net income (loss)	$	(5,030	)	$	2,008		$	(4,254	)	$	2,775
Denominator:
Basic – weighted shares outstanding		8,743			6,991			8,724			6,930
Weighted shares assumed upon exercise of stock awards		—			1,127			—			1,091
Diluted – weighted shares outstanding		8,743			8,118			8,724			8,021
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	(0.40	)	$	0.34		$	(0.29	)	$	0.48
Discontinued operations		(0.17	)		(0.05	)		(0.20	)		(0.08	)
Net income (loss) per share:	$	(0.57	)	$	0.29		$	(0.49	)	$	0.40
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	(0.40	)	$	0.29		$	(0.29	)	$	0.42
Discontinued operations		(0.17	)		(0.04	)		(0.20	)		(0.07	)
Net income (loss) per share:	$	(0.57	)	$	0.25		$	(0.49	)	$	0.35

19

The dilutive impact summarized above relates to the periods when the average market price of Company stock exceeded the exercise price of the potentially dilutive options. Earnings per common share was based on the weighted average number of common shares outstanding during the periods when computing the basic earnings per share. When dilutive, stock options are included as equivalents using the treasury stock method when computing the diluted earnings per share. Shares represented by RSUs are also included in the dilution calculation. Individual components of basic and diluted income per share may not sum to the total income per share due to rounding.

For the three and six months ended June 30, 2019, 563 options and 138 RSUs and 575 options and 137 RSUs were excluded from the dilutive calculation, respectively, as their effect would have been antidilutive based on losses in the period.

15. Legal Proceedings

The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or advised the Company that they need to investigate further. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, many of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company’s consolidated financial position or results of operations.

The Company is also involved in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect our consolidated financial position, liquidity or results of operations.

16. Related-Party Transactions

The Company uses the law firm of Blank Rome LLP for legal services. A partner of that firm is the son-in-law of the Chairman of the Company’s Board of Directors, however, on May 1, 2019, the Chairman retired from the Company’s Board of Directors. For the three and six months ended June 30, 2019, the Company paid that firm approximately $35 and $106 for legal services and costs. For the three and six months ended June 30, 2018, the Company paid that firm approximately $72 and $175, respectively, for legal services and costs. The prior Chairman of our Board of Directors was considered independent under applicable Nasdaq and Securities and Exchange Commission rules because (i) no payments were made to the Chairman or the partner directly in exchange for the services provided by the law firm and (ii) the amounts paid to the law firm did not exceed the thresholds contained in the Nasdaq standards. Furthermore, the aforementioned partner does not provide any legal services to the Company and is not involved in billing matters.

In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience, an entity in which we owned 49% of the equity, for 1,750 Euros and the transfer back of our 49% ownership interest in Soundperience. See Note 9.

20

17. Revenue by Market

The following tables set forth, for the periods indicated, timing of revenue recognition by market:

Timing of revenue recognition for the three months ended June 30, 2019:

	Products and services transferred at point in time		Products and services transferred over time		Total
Medical Biotelemetry:
Diabetes	$	—	$	17,950	$	17,950
Other Medical		—		2,942		2,942
Hearing Health:
Value Based DTEC		1,736		—		1,736
Value Based ITEC		2,399		—		2,399
Legacy OEM		2,540		—		2,540
Professional Audio Communications:		1,769		—		1,769
Total Net Revenue	$	8,444	$	20,892	$	29,336

Timing of revenue recognition for the six months ended June 30, 2019:

	Products and services transferred at point in time		Products and services transferred over time		Total
Medical Biotelemetry:
Diabetes	$	—	$	35,114	$	35,114
Other Medical		—		6,571		6,571
Hearing Health:
Value Based DTEC		3,366		—		3,366
Value Based ITEC		4,976		—		4,976
Legacy OEM		5,343		—		5,343
Professional Audio Communications:		3,536		—		3,536
Total Net Revenue	$	17,221	$	41,685	$	58,906

21

Timing of revenue recognition for the three months ended June 30, 2018:

	Products and services transferred at point in time		Products and services transferred over time		Total
Medical Biotelemetry:
Diabetes	$	—	$	17,307	$	17,307
Other Medical		—		2,891		2,891
Hearing Health:
Value Based DTEC		2,052		—		2,052
Value Based ITEC		2,634		—		2,634
Legacy OEM		3,044		—		3,044
Professional Audio Communications:		1,520		—		1,520
Total Net Revenue	$	9,250	$	20,198	$	29,448

Timing of revenue recognition for the six months ended June 30, 2018:

	Products and services transferred at point in time		Products and services transferred over time		Total
Medical Biotelemetry:
Diabetes	$	—	$	30,869	$	30,869
Other Medical		—		5,262		5,262
Hearing Health:
Value Based DTEC		3,837		—		3,837
Value Based ITEC		4,608		—		4,608
Legacy OEM		6,101		—		6,101
Professional Audio Communications:		3,349		—		3,349
Total Net Revenue	$	17,895	$	36,131	$	54,026

22

ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Business Overview

Headquartered in Arden Hills, Minnesota, IntriCon Corporation (together with its subsidiaries referred to as the “Company”, “IntriCon,” “we”, “us” or “our”) is an international company engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. In addition to its operations in Minnesota, the Company has facilities in Illinois, Singapore, Indonesia, and Germany.

On June 25, 2019, the Company’s officers, pursuant to delegated authority from the board, approved plans to discontinue the operations of its United Kingdom (UK) subsidiary within our body worn device segment. For all periods presented, the Company classified this business as discontinued operations, and accordingly, has reclassified historical financial data presented herein.

The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.

The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In February 2016, the FASB issued ASU 2016-02 “Leases” (Topic 842). Topic 842 supersedes the lease accounting guidance previously set forth in the Accounting Standards Codification (ASC) Topic 840 “Leases,” and requires lessees to recognize a lease liability and a right-of-use asset for all leases that extend beyond one year. The Company adopted Topic 842 with a date of initial application of January 1, 2019.

Information contained in this section of this Quarterly Report on Form 10-Q and expressed in U.S. dollars is presented in thousands (000s), except for per share data and as otherwise noted. In addition, all information included in Item 2 is related to continuing operations unless otherwise noted.

Market Overview

IntriCon serves the body-worn device market by designing, developing, engineering, manufacturing and distributing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the medical biotelemetry market, the emerging value based hearing healthcare market, the hearing health direct-to-end-consumer market and the professional audio communication market. Revenue from markets is reported on the respective medical biotelemetry, hearing health, hearing health direct-to-end-consumer and professional audio lines in the discussion of our results of operations in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 17 “Revenue by Market” to the Company’s consolidated condensed financial statements included herein.

Hearing Healthcare Market

In the United States alone, there are approximately 40 million adults that report some degree of hearing loss. In adults, the most common cause of hearing loss is aging and noise. In fact, by the age of 65, one out of three people have hearing loss. The hearing-impaired population is expected to grow significantly over the next decade due to an aging population and more frequent exposure to loud sounds that can cause noise-induced hearing loss. It is estimated that hearing aids can help more than 90 percent of people with hearing loss, however the current market penetration into the U.S. hearing impaired population is approximately 20 percent, a percentage that has remained essentially unchanged for the last four decades. The primary deterrents to greater penetration are cost and access. Along with this, the legacy hearing aid distribution channel is an oligopoly of six large hearing aid manufacturers who utilize bricks and mortar and licensed audiologists to sell devices while controlling the channel dynamics. As a result, the average cost of a hearing aid sold in the US market today is over $2,400 per device, more than double the cost from fifteen years ago. Approximately 70 percent of the hearing impaired have hearing loss in both ears (referred to as a binaural loss), driving the total cost to almost $5,000 on average for a set of hearing aids.

23

Today in the US market, the legacy channel pushes all hearing impaired through the same inefficient, costly channel. However, a very large portion of the hearing-impaired market – mostly notably those with mild to moderate losses – could be better served with the proper combination of high quality, outcome-based devices, advanced fitting software and consumer services/care best practices – all at much lower cost. We believe fundamental change is needed and are excited about the opportunity that we created through thoughtful hard work and planning: a chance to deliver superior outcomes-based affordable hearing healthcare, by combining state-of-the-art devices and software technology, along with best practices customer service and at a much lower cost directly to consumers across the country, many of whom have not been able to afford care previously.

We believe a perfect vortex of factors has come together over the last few years to enable the emergence of a market disruptive, high-quality, low cost distribution model. These factors include the continued consolidation of retail (causing escalating hearing aid prices), consumer outcry, consumer education, advancements in technology (such as behind-the-ear devices, advanced digital signal processing, low-power wireless, and self-fitting software) as well as regulatory actions and pronouncements by the U.S. Food and Drug Administration (FDA), the President’s Council of Advisors on Science and Technology and the National Academies of Science, Engineering and Medicine.

In early January 2016, the FDA weighed in on low hearing aid penetration rates with an announcement that highlighted statistics from the National Institute on Deafness and Other Communication Disorders. They found that 37.5 million U.S. adults aged 18 and older report some form of hearing loss. However, only 30 percent of adults over 70, and 16 percent of those aged 20 to 69, who could benefit from wearing hearing aids, have ever used them. Based on these statistics, the FDA reopened the public comment period on draft guidance related to the agency’s premarket requirements for hearing aids and personal sound amplifiers (PSAPs). In April 2016, the FDA hosted a public workshop to, among other things, gather stakeholder and public input on draft guidance related to the agency’s premarket requirements for hearing aids and PSAPs. The FDA’s intent was to consider ways in which it can most effectively regulate hearing aids to promote accessibility and affordability while encouraging innovation. In December 2016, the FDA announced important steps to better support consumer access to hearing aids. The agency issued a guidance document explaining that it does not intend to enforce the requirement that individuals age 18 and older receive a medical evaluation or sign a waiver prior to purchasing most hearing aids, effective immediately. It also announced its commitment to consider creating a category of over-the-counter (OTC) hearing aids.

Furthermore, there were significant public policy developments during 2017. On August 18, 2017, President Donald Trump signed into law H.R. 2430, the FDA Reauthorization Act of 2017, which included a section concerning the regulation of OTC hearing aids. The law is designed to enable adults with mild to moderate hearing loss to access OTC hearing aids without being seen by a hearing care professional. The law requires the FDA to create and regulate a category of OTC hearing aids to ensure they meet the same high standards for safety, consumer labeling, and manufacturing protection that all other medical devices must meet. Additionally, the law mandates that the FDA establish an OTC hearing aid category for adults with “perceived” mild to moderate hearing loss within three years of passage of the legislation. The FDA also must finalize a rule within 180 days after the close of the comment period, detailing what level of safety, labeling and consumer protections will be included. We believe this law has the potential to remove the significant barriers existing today that prevent innovative hearing health solutions. We believe that this law will invigorate competition, spur innovation and facilitate the development of an ecosystem of hearing health care that provides affordable and accessible solutions to millions of unserved or underserved Americans. Today, IntriCon serves both the value-based hearing healthcare channel and the legacy hearing health channel.

24

Value-Based Hearing Healthcare 

The Company believes the value-based hearing healthcare (VBHH) market offers significant growth opportunities. In contrast to the legacy channel dynamics, the VBHH market channel is flexible and able to serve the end consumer through a variety of modalities which may include self-fitting, remote programing and adjustments, customer support call centers and bricks and mortar stores. The average price of a hearing aid sold through this channel is less than twenty-five percent of the average $2,400 device price typically sold through the legacy channel. The Company recently commissioned an ethnographic research study, which identified a $3+ billion annual VBHH market opportunity, fueled by an immediate addressable market of 6.8 million dissatisfied hearing aid users and 6.6 million current non-hearing aid users. In addition, this study assisted us in identifying our customer, various customer segmentations and personas. To best approach this market opportunity, we have focused our efforts to serve both the value-based Direct-to-End-Consumer (DTEC) and value-based Indirect-to-End-Consumer (ITEC) channels. Over the past decade we have invested in the manufacturing footprint, product technology and fitting software to provide individuals access to affordable, quality outcomes-based hearing healthcare.

Our DTEC represents a channel that sells products and services directly to the end consumer, which today consists of our HHE business. In December of 2017, we purchased the remaining 80% of HHE, a direct-to-end-consumer mail order hearing aid provider. However, the Company had been preparing to address this market long before the acquisition of HHE and has spent the last decade investing in the technology and low-cost manufacturing to design and build superior devices and fitting solutions. With this acquisition, we believe we now have the channel infrastructure to directly reach consumers and—importantly for millions—the ability to offer high-quality hearing healthcare at a fraction of the cost. The Company’s devices and technologies coupled with HHE’s high-touch care, outcomes based, and hassle free telemedicine model has created a complete eco-system of hearing healthcare in which the Company intends to serve the $3+ billion market. Through our other VBHH initiatives and tests, we have formed alliances with other key partners, which have given us experience and vital insight as we move aggressively into a more consumer-facing role. HHE provides an efficient, direct-to-end-consumer channel to reach consumers who likely do not have insurance covering hearing devices. This is a channel that we can build on and expand via technology—and one that is complementary with many of our existing relationships.

The Company is also focused on serving its value-based ITEC customers, who also sell products and services directly to the end consumer. We have established ourselves as a leader in supplying this portion of the market with advanced, outcome-based products and accessories. The Company has formed strong relationships with various customers in the channel, including insurance providers, and geriatric product retailers and other indirect-to-end-consumer hearing aid providers.

In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience, positioning the Company to capitalize on the upcoming OTC hearing aid regulations. Sentibo Smart Brain self-fitting software is designed to improve both channel productivity and the quality of first-time fittings, resulting in lower prices, greater access and increased customer satisfaction.

We strongly believe that incorporating self-fitting technology is a critical step in creating our high-quality, low-cost hearing healthcare ecosystem. The Sentibo Smart Brain self-fitting software technology has the potential to drastically reduce the price of hearing aids, drive greater access and increase customer satisfaction.

Legacy Hearing Health Channel

We also believe there are niches in the legacy hearing health channel that will embrace our outcomes-based products and technologies in the United States and Europe. High costs of legacy devices and retail consolidation have constrained the growth potential of the independent audiologist and dispenser. We believe our software and product offering can provide independent audiologists and dispensers the ability to compete with larger retailers, such as Costco, and manufacturer owned retail distributors.

Medical Biotelemetry

In the medical biotelemetry market, the Company is focused on sales of biotelemetry devices for life-critical diagnostic monitoring. The Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete biotelemetry devices for leading and emerging medical device manufacturers. The medical industry is faced with pressures to reduce the cost of healthcare. Driven by its core technologies, IntriCon helps shift the point of care from expensive traditional settings, such as hospitals, to less expensive non-traditional settings like the home. IntriCon currently serves this market by offering medical manufacturers the capabilities to design, develop, manufacture and distribute medical devices that are easier to use, are more miniature, use less power, and are lighter. Increasingly, the medical industry is looking for wireless, low-power capabilities in their devices.

25

IntriCon currently has a presence in the diabetes, cardiac and catheter positioning markets. For diabetes, IntriCon works with Medtronic to manufacture their wireless continuous glucose monitors (CGM), sensor assemblies, and accessories associated with Medtronic’s insulin pump and CGM system. In August 2016, the FDA approved the MiniMed 630G system which is intended to replace Medtronic’s MiniMed 530G system. In September 2016, the FDA approved the next generation MiniMed 670G insulin pump system, into which IntriCon components are also designed. The MiniMed 670G is the world’s first hybrid closed loop insulin delivery system and we are excited that our components are designed into and support such a revolutionary diabetes management system. In June 2017, the 670G was launched in the U.S. and Medtronic began fulfilling orders from patients enrolled in their Priority Access Program. In parallel, Medtronic began taking new orders from interested customers who want to be next in line to receive the system after the Priority Access orders are filled. In March 2018, the FDA approved the Guardian Connect, Medtronic’s standalone CGM system that allows patients to stay ahead of high and low glucose events. Looking ahead, we believe there are opportunities to expand our diabetes product offering with Medtronic, as well as move into new markets outside of the diabetes market.

IntriCon has a suite of medical coils and micro coils that it offers to various original equipment manufacturing (OEM) customers. These products are currently used in pacemaker programming and interventional catheter positioning applications. We recently secured a new large medical customer for our proprietary medical coils to be used for pacemaker programming in their devices.

IntriCon manufactures bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system as well as a family of safety needle products for an OEM customer that utilizes IntriCon’s insert and straight molding capabilities. These products are assembled using full automation, including built-in quality checks within the production lines.

Throughout 2018, we expanded our infrastructure to support anticipated growth from current medical biotelemetry customers and future growth from increased business development. Expansion efforts in 2018 included a newly leased 37,000-square-foot medical biotelemetry manufacturing and clean room facility in Minnesota, an additional 10,000-square-foot medical assembly space in Singapore, 13 new molding presses and a high-speed printed circuit board assembly line. In addition to these investments, our current customers invested several million dollars in tooling and automation within our facilities. While we have begun limited production on certain products in our new facilities, we are still working with current medical biotelemetry customers to complete required validation and qualification of several key production lines. We anticipate having all validation and qualification of our equipment and production lines related to the recent expansion complete by the end of 2019.

The Company is committed to increasing investments to support its medical biotelemetry business development efforts. In early 2019, the Company hired a vice president of medical business development to leverage our core competencies and diversify our medical revenue base. The Company believes it has a significant opportunities to serve the emerging biotelemetry and home care markets through its already developed core competencies and capabilities to develop devices that are more technologically advanced, smaller and lightweight.

Professional Audio Communications

IntriCon entered the high-quality audio communication device market in 2001, and now has a line of miniature, professional audio headset products used by customers focusing on emergency response needs. The line includes several communication devices that are extremely portable and perform well in noisy or hazardous environments. These products are well suited for applications in the fire, law enforcement, safety, aviation and military markets. In addition, the Company has a line of miniature ear- and head-worn devices used by performers and support staff in the music and stage performance markets.

Core Technologies Overview:

Our core technologies expertise is focused on four main markets: medical biotelemetry, hearing health, hearing health direct-to-end-consumer and professional audio communications. Over the past several years, the Company has increased investments in the continued development of five critical core technologies: Ultra-Low-Power (ULP) Digital Signal Processing (DSP), ULP Wireless, Fitting Software, Microminiaturization, and Miniature Transducers. These five core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable, more advanced devices and the need for greater efficiencies in the delivery models. The continued advancements in this area have allowed the Company to further enhance the mobility and effectiveness of miniature body-worn devices. 

26

ULP DSP  

DSP converts real-world analog signals into a digital format. Through our nanoDSP™ technology, IntriCon offers an extensive range of ULP DSP amplifiers for hearing, medical and professional audio applications. Our proprietary nanoDSP incorporates advanced ultra-miniature hardware with sophisticated signal processing algorithms to produce devices that are smaller and more effective. The Company further expanded its DSP portfolio including improvements to its Reliant CLEAR™ feedback canceller, offering increased added stable gain and faster reaction time. Additionally, the DSP technologies are utilized in the Audion8™, our eight-channel hearing aid amplifier, and the Audion16™, our wide dynamic range compression sixteen-channel hearing aid amplifier. The amplifiers are feature-rich and are designed to fit a wide array of applications. In addition to multiple compression channels, the amplifiers have a complete set of proven adaptive features which greatly improve the user experience.

ULP Wireless  

Wireless connectivity is fast becoming a required technology, and wireless capabilities are especially critical in new body-worn devices. IntriCon’s platform of wireless technology offers solutions for transmitting the body’s activities to caregivers and wireless audio links for professional communications and surveillance products, including diabetes monitoring and audio streaming for hearing devices.

IntriCon has completed the commercialization of the third generation of Physiolink (Physiolink 3) wireless technology, which will be incorporated into product platforms serving the medical biotelemetry, hearing health, hearing health direct-to-end-consumer and professional audio communication markets. This system is based on 2.4GHz proprietary digital radio protocol in the industrial-scientific-medical (ISM) frequency band and enables audio and data streaming and command and control to ear-worn and body-worn applications over distances of up to ten meters. The Physiolink 3 technology can be used to increase productivity in the emerging VBHH channels through in office wireless programming, remote cloud based fitting and consumer directed self-fitting of hearing aids. This will provide both greater access and lower costs for patients. In addition, remote control functions will improve the patient experience while using the device especially for those with diminished dexterity. The Physiolink 3 technology builds on the Physiolink 2 capabilities by adding wireless streaming at, what we believe, are much lower power levels than any technology currently on the market. This will allow for accessories to enhance the user experience in noisy environments by allowing audio streaming directly to the hearing aid.

Fitting Software 

The ability to efficiently and effectively fit hearing aids is critical to building a value based eco-system of hearing healthcare. By developing more advanced fitting software systems, individuals can benefit from fittings that conform to their specific loss, while eliminating the need for an in-person appointment. In addition to the traditional fitting software, IntriFit, used in the conventional channel, IntriCon has made significant investments in various advanced fitting software solutions, including its purchase of the source code for the Sentibo Smart Brain self-fitting software, that can enable remote and self-fitting solutions. IntriCon believes these advanced fitting solutions, along with the other components of the eco-system, will drive access, affordability and superior customer satisfaction to the millions of individuals that cannot receive care today, primarily due to high cost and low access.

In January 2019, the Company purchased the source code for the Sentibo Smart Brain self-fitting software from Soundperience. The Sentibo Smart Brain System is the first psycho-acoustic way of analyzing peripheral hearing and central hearing processing. It was developed by an international research team based on the latest scientific findings from the fields of audiology and brain research. We believe this software technology is a critical component to our domestic value-based hearing healthcare model. Sentibo, as well as our other proprietary fitting systems, are designed to improve both channel productivity and the quality of first-time fittings, resulting in lower prices, greater access and increased customer satisfaction. IntriCon expects to introduce our advanced fitting solutions through our various VBHH channels in 2019.

Microminiaturization 

IntriCon excels at miniaturizing body-worn devices. We began honing our microminiaturization skills over 30 years ago, supplying components to the hearing health industry. Our core miniaturization technology allows us to make devices for our markets that are one cubic inch and smaller. We also are specialists in devices that run on very low power, as evidenced by our ULP wireless and DSP. Less power means a smaller battery, which enables us to reduce size even further, and develop devices that fit into the palm of one’s hand.

27

Miniature Transducers 

IntriCon’s advanced transducer technology has been pushing the limits of size and performance for over a decade. Included in our transducer line are our miniature medical coils and micro coils used in pacemaker programming and interventional catheter positioning applications. We believe that with the increase of greater interventional care, our coil technology harbors significant value.

Forward-Looking and Cautionary Statements

Certain statements included in this Quarterly Report on Form 10-Q or documents the Company files with the Securities and Exchange Commission, which are not historical facts, or that include forward-looking terminology such as “may”, “will”, “believe”, “anticipate”, “expect”, “should”, “optimistic” “continue”, “estimate”, “intend”, “plan”, “would”, “could”, “guidance”, “potential”, “opportunity”, “project”, “forecast”, “confident”, “projections”, “schedule”, “designed”, “future”, “discussion”, “if” or the negative thereof or other variations thereof, are forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, and the regulations thereunder), which are intended to be covered by the safe harbors created thereby. These statements may include, but are not limited to statements in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Notes to the Company’s Condensed Consolidated Financial Statements” such as net operating loss carryforwards, the ability to meet cash requirements for operating needs, the ability to meet liquidity needs, assumptions used to calculate future level of funding of employee benefit plans, the adequacy of insurance coverage and the impact of new accounting pronouncements and litigation. Forward-looking statements also include, without limitation, statements as to the Company’s expected future results of operations and growth, strategic alliances and their benefits, government regulation, potential increases in demand for the Company’s products, the Company’s ability to meet working capital requirements, the Company’s business strategy, the expected increases in operating efficiencies, anticipated trends in the Company’s markets, estimates of goodwill impairments and amortization expense of other intangible assets, the effects of changes in accounting pronouncements, the effects of litigation and the amount of insurance coverage, and statements as to trends or the Company’s or management’s beliefs, expectations and opinions.

Forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements. In addition to the factors discussed in this Quarterly Report on Form 10-Q, certain risks, uncertainties and other factors can cause actual results and developments to be materially different from those expressed or implied by such forward-looking statements, including, without limitation, the following:

■ our ability to successfully implement our business and growth strategy;

■ risks arising in connection with the insolvency of our former subsidiary, Selas SAS, and potential liabilities and actions arising in connection with the insolvency;

■ the volume and timing of orders received by the Company, particularly from Medtronic and hi Health;

■ changes in estimated future cash flows;

■ our ability to collect our accounts receivable;

■ foreign currency movements in markets that we serve;

■ changes in the global economy and financial markets;

■ weakening demand for our products due to general economic conditions;

■ changes in the mix of products sold;

■ our ability to meet demand;

28

■ changes in customer requirements;

■ FDA approval, timely release and acceptance of our products and the products of our customers;

■ competitive pricing pressures;

■ pending and potential future litigation;

■ cost and availability of electronic components and commodities for our products;

■ our ability to create and market products in a timely manner and develop products that are inexpensive to manufacture;

■ the loss of one or more of our major customers;

■ our ability to identify, complete and integrate acquisitions;

■ effects of legislation;

■ effects of foreign operations;

■ our ability to develop new products;

■ our ability to recruit and retain engineering and technical personnel;

■ the costs and risks associated with research and development investments;

■ our ability and the ability of our customers to protect intellectual property;

■ cybersecurity threats;

■ loss of members of our senior management team; and

■ other risk factors set forth in our most recent Annual Report on Form 10-K or any prior Quarterly Report on Form 10-Q, which are incorporated by reference into this Report.

For a description of these and other risks, see Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other risks described elsewhere in this Quarterly Report on Form 10-Q, or in other filings the Company makes from time to time with the Securities and Exchange Commission. The Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

Critical Accounting Policies

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make certain assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period.

Certain accounting estimates and assumptions are particularly sensitive because their significance to the consolidated condensed financial statements and the possibility that future events affecting them may differ markedly. The accounting policies of the Company with significant estimates and assumptions include the Company’s revenue recognition, accounts receivable reserves, inventory valuation, goodwill, long-lived assets, deferred taxes policies, employee benefit obligations, lease assets and liabilities and investment securities. These and other significant accounting policies are described in and incorporated by reference from “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and Note 1 to the consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

29

Results of Operations

Revenue, net

Below is a summary of our revenue by main markets for the three and six months ended June 30, 2019 and 2018:

					Change
Three Months Ended June 30	2019		2018		Dollars			Percent
Medical Biotelemetry:
Diabetes	$	17,950	$	17,307	$	643			3.7	%
Other Medical		2,942		2,891		51			1.8	%
Total	$	20,892	$	20,198	$	694			3.4	%
Hearing Health:
Value Based DTEC	$	1,736	$	2,052	$	(316	)		-15.4	%
Value Based ITEC		2,399		2,634		(235	)		-8.9	%
Legacy OEM		2,540		3,044		(504	)		-16.6	%
Total	$	6,675	$	7,730	$	(1,055	)		-13.6	%
Professional Audio Communications	$	1,769	$	1,520	$	249			16.4	%
Total Net Revenue	$	29,336	$	29,448	$	(112	)		-0.4	%

					Change
Six Months Ended June 30	2019		2018		Dollars			Percent
Medical Biotelemetry:
Diabetes	$	35,114	$	30,869	$	4,245			13.8	%
Other Medical		6,571		5,262		1,309			24.9	%
Total	$	41,685	$	36,131	$	5,554			15.4	%
Hearing Health:
Value Based DTEC	$	3,366	$	3,837	$	(471	)		-12.3	%
Value Based ITEC		4,976		4,608		368			8.0	%
Legacy OEM		5,343		6,101		(758	)		-12.4	%
Total	$	13,685	$	14,546	$	(861	)		-5.9	%
Professional Audio Communications	$	3,536	$	3,349	$	187			5.6	%
Total Net Revenue	$	58,906	$	54,026	$	4,880			9.0	%

30

For the three and six months ended June 30, 2019, we experienced an increase of 3.7% and 13.8% in net revenue in the diabetes medical biotelemetry market compared to the same period in 2018. Medtronic revenues were up year-over-year driven by market share growth for legacy products and the introduction of new products. IntriCon currently serves this market by offering medical manufacturers the capabilities to design, develop and manufacture medical devices that are easier to use, are more miniature, use less power, and are lighter. IntriCon has a strong presence in the diabetes market with its Medtronic partnership. The Company believes there are growth opportunities in this market as well as other emerging biotelemetry and home care markets that could benefit from its capabilities to develop devices that are more technologically advanced, smaller and lightweight.

All other medical net revenue for the three and six months ended June 30, 2019 increased 1.8% and 24.9%, respectively, compared to the same period in 2018. The increase was driven by the addition of a new customer in our medical coils business.

Net revenue in our hearing health value based direct-to-end-consumer business for the three and six months ended June 30, 2019 decreased 15.4% and 12.3%, respectively, compared to the same period in 2018.

Net revenue in our hearing health value based indirect-to-end-consumer business for the three and six months ended June 30, 2019 decreased 8.9% and increased 8.0%, respectively, compared to the same period in 2018. The modest revenue decrease during the quarter was largely due order delays associated with restructuring activity within a large insurance customer’s hearing health business.

Net revenue in our hearing health legacy business for the three and six months ended June 30, 2019 decreased 16.6% and 12.4%, respectively, compared to the same period in 2018.

Net revenue to the professional audio device sector increased 16.4% and 5.6% for the three and six months ended June 30, 2019, respectively, compared to the same period in 2018. IntriCon will continue to leverage its core technology in professional audio to support existing customers, as well as pursue related hearing health and medical product opportunities.

Gross profit

Gross profit, both in dollars and as a percent of revenue, for the three and six months ended June 30, 2019 and 2018, was as follows:

	2019					2018					Change
			Percent					Percent
Three Months Ended June 30	Dollars		of Revenue			Dollars		of Revenue			Dollars			Percent
Gross Profit	$	8,215		28.0	%	$	9,721		33.0	%	$	(1,506	)		-15.5	%

	2019					2018					Change
			Percent					Percent
Six Months Ended June 30	Dollars		of Revenue			Dollars		of Revenue			Dollars			Percent
Gross Profit	$	16,773		28.5	%	$	17,824		33.0	%	$	(1,051	)		-5.9	%

The 2019 gross profit decreased over the comparable prior year period primarily due to the ongoing validation and qualification expense as well as excess capacity related to the recent manufacturing expansion to meet the higher volume requirements of our existing and future customers.

31

Sales and Marketing, General and Administrative and Research and Development Expenses

Sales and marketing, general and administrative and research and development expenses for the three and six months ended June 30, 2019 and 2018 were as follows:

	2019					2018					Change
			Percent					Percent
Three Months Ended June 30	Dollars		of Revenue			Dollars		of Revenue			Dollars			Percent
Sales and Marketing	$	3,072		10.5	%	$	2,637		9.0	%	$	435			16.5	%
General and Administrative		3,650		12.4	%		2,751		9.3	%		899			32.7	%
Research and Development		1,097		3.7	%		1,316		4.5	%		(219	)		-16.6	%

	2019					2018					Change
			Percent					Percent
Six Months Ended June 30	Dollars		of Revenue			Dollars		of Revenue			Dollars			Percent
Sales and Marketing	$	6,461		11.0	%	$	5,240		9.7	%	$	1,221			23.3	%
General and Administrative		6,836		11.6	%		5,502		10.2	%		1,334			24.2	%
Research and Development		2,062		3.5	%		2,475		4.6	%		(413	)		-16.7	%

Sales and marketing expenses increased over the prior year periods due to increased DTEC marketing, support costs and wages. General and administrative expenses were greater than the prior year periods primarily due to increased other outside services, support costs and non-cash stock compensation expense. Research and development decreased over the prior year periods due to a reduction in outside service and support costs.

Impairment loss

Impairment loss for the three and six months ended June 30, 2019 was $3,765. There were no impairment losses identified for the comparable prior year periods. The impairment losses related to a write-off of goodwill and intangible assets due to negative cash flows within our Hearing Help Express reporting unit.

Interest income (expense), net

Interest income (expense), net for the three and six months ended June 30, 2019 was $248 and $463 compared to ($211) and ($405) for the comparable three and six month periods in 2018. This increase was due to the payoff of all of our credit facility debt in 2018 which reduced our interest expense along with interest income earned in the current year on our investment accounts.

Other expense, net

Other expense, net for the three and six months ended June 30, 2019 was $272 and $406 compared to $196 and $401 for the same period in 2018.

Income tax expense

Income tax expense for the three and six months ended June 30, 2019 was $116 and $247 compared to $269 and $455 for the same period in 2018.

32

Liquidity and Capital Resources

As of June 30, 2019, we had $9,801 of cash on hand. Sources of our cash for the six months ended June 30, 2019 have been from our operating activities, as described below. The Company’s cash flows from operating, investing and financing activities, as reflected in the statement of cash flows, are summarized as follows:

	Six Months Ended
	June 30, 2019			June 30, 2018
Cash provided by (used in) from continuing operations:
Operating activities	$	2,175		$	1,026
Investing activities		(196	)		(2,147	)
Financing activities		(100	)		2,156
Effect of exchange rate changes on cash		(8	)		(96	)
Net increase in cash from continuing operations	$	1,871		$	939

The most significant items that contributed to the $2,175 of cash provided by operating activities were non-cash add backs for impairment loss, depreciation and amortization and stock-based compensation expense, as well as a decrease in accounts receivable and other current assets partially offset by decreases in accounts payable and accrued expenses as well as increases in contract assets.

Net cash used in investing activities of ($196) primarily consisted of purchases of machinery and equipment, investment securities and other assets along with our investments in partnerships partially offset by proceeds from sale and maturity of investment securities.

Net cash used in financing activities of ($100) was comprised primarily from the withholding of shares from vesting RSU awards to pay withholding taxes and the payment of financing leases partially offset by cash received from the exercise of stock options and employee stock purchase plan shares.

The Company had the following bank arrangements:

Domestic Credit Facilities

The Company and its domestic subsidiaries are parties to a credit facility with CIBC Bank USA. The credit facility, as amended through June 30, 2019, provides for a $7,000 revolving credit facility, with a $200 sub facility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of the Company’s eligible trade receivables and eligible inventory, and eligible equipment less a reserve. The credit facility matures on December 15, 2022.

On April 17, 2019, the Company entered into a Thirteenth Amendment to the Loan and Security Agreement

with CIBC Bank USA which: reduced our borrowing capacity to its current $7,000 level; lessened restrictions surrounding acquisitions, business investments, distributions and disposition of assets; eliminated the mandatory prepayment requirement with respect to proceeds from asset sales and capital and debt financings; and eliminated the annual capital expenditure covenant.

The Company was in compliance with all applicable covenants under the credit facility as of June 30, 2019.

Foreign Credit Facility

In addition to its domestic credit facilities, the Company’s wholly-owned subsidiary, IntriCon, PTE LTD., has an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for an asset-based line of credit. Borrowings bear interest at a rate of .75% to 2.5% over the lender’s prevailing prime lending rate.

Capital Adequacy

We believe that funds raised from our August 2018 public offering, funds expected to be generated from operations and funds available under our revolving credit loan facility will be sufficient to meet our anticipated cash requirements for operating needs for at least the next 12 months. While management believes that we will be able to meet our liquidity needs for at least the next 12 months, no assurance can be given that we will be able to do so.

As of June 30, 2019, and December 31, 2018, the Company had a total borrowing capacity of $9,575 and $13,884, respectively, with no borrowings outstanding at each reporting period.

33

ITEM 3.Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

ITEM 4.Controls and Procedures

The Company’s management, with the participation of its chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), as of June 30, 2019 (the “Disclosure Controls Evaluation”). Based on the Disclosure Controls Evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective to provide a reasonable level of assurance that: (i) information required to be disclosed by the Company in the reports the Company files or submits under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) information required to be disclosed in the reports the Company files or submits under Exchange Act is accumulated and communicated to management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure, all in accordance with Exchange Act Rule 13a-15(e).

Except for the implementation of certain internal controls related to the adoption of the new lease standard (Topic 842), there were no changes in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f), during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

34

PART II - OTHER INFORMATION

ITEM 1.Legal Proceedings

The information contained in Note 15 to the Consolidated Condensed Financial Statements in Part I of this quarterly report is incorporated by reference herein.

ITEM 1A.Risk Factors

In addition to the foregoing and the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect the Company’s business, financial condition or future results. The risk factors in the Company’s Annual Report on Form 10-K have not materially changed. The risks described in our Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3.Defaults upon Senior Securities

None.

ITEM 4.Mine Safety Disclosures.

Not applicable.

ITEM 5.Other Information

None.

35

 
ITEM 6.Exhibits

(a) Exhibits

10.1	Thirteenth Amendment to Loan and Security Agreement among the Company, IntriCon, Inc., Hearing Help Express, Inc. and CIBC Bank USA (formerly known as The PrivateBank and Trust Company), dated as of April 17, 2019 (incorporated by reference from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).
10.2	Amended and Restated Revolving Note from the Company, IntriCon, Inc. and Hearing Help Express, Inc. to CIBC Bank USA (formerly known as The PrivateBank and Trust Company), dated April 17, 2019 (incorporated by reference from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).
31.1*	Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of principal executive officer pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of principal financial officer to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following materials from IntriCon Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Condensed Balance Sheets as of June 30, 2019,  (Unaudited) and December 31, 2018; (ii) Consolidated Condensed Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2019, and 2018; (iii) Consolidated Condensed Statements of Comprehensive Income (Unaudited) for the Three and Six Months Ended June 30, 2019, and 2018; (iv) Consolidated Condensed Statements of Equity (Unaudited) for the Six Months Ended June 30, 2019, and 2018; (v) Consolidated Condensed Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2019, and 2018; and (vi) Notes to Consolidated Condensed Financial Statements (Unaudited)*

* Filed herewith.

36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		INTRICON CORPORATION
		(Registrant)
Date: August 9, 2019	By:	/s/ Mark S. Gorder
	Mark S. Gorder
	President and Chief Executive Officer
	(principal executive officer)
Date: August 9, 2019
	By:	/s/ Scott Longval
	Scott Longval
	Executive Vice President, Chief Operating Officer, Chief Financial Officer and Secretary
	(principal financial officer)

37